We are pursuing a precision medicine approach to develop a broad range of therapeutics for neurodegenerative diseases
Our strategy is to first develop novel drug candidates for genetically defined patient sub-populations. Our longer-term goal is to develop therapeutics for larger patient populations, leveraging the learnings from our precision-based programs.
For our initial microglia-targeted programs aimed at TREM2 activation, we are developing both large molecule (an infusible antibody) and orally available small molecule drugs. Our strategy of developing the small molecule TREM2 therapeutic in addition to an antibody is because an orally delivered drug should have meaningful clinical and commercial advantages in large chronic indications, such as AD, especially when treatment is administered in the outpatient setting.
